Dogwood Therapeutics Inc. (DWTX)
NASDAQ (CM) NASDAQ (CM) Primary 
Dogwood Therapeutics, Inc. (DWTX) Discusses Halneuron and Pipeline Advances for Chemotherapy-Induced Neuropathic Pain Transcript
Dogwood Therapeutics, Inc. (DWTX) Discusses Halneuron and Pipeline Advances for Chemotherapy-Induced Neuropathic Pain Transcript
Dogwood Therapeutics Nears Phase 2b Readout for Halneuron Neuropathic Pain Treatment
Dogwood Therapeutics NASDAQ: DWTX said its Phase 2b study of Halneuron, an investigational treatment for chemotherapy-induced neuropathic pain, has enrolled more than 230 patients and is expected to report top-line data later this fall.
Dogwood Therapeutics, Inc. (DWTX) Shareholder/Analyst Call Prepared Remarks Transcript
Dogwood Therapeutics, Inc. (DWTX) Shareholder/Analyst Call Prepared Remarks Transcript
Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 1.7% – Time to Buy?
Shares of Dogwood Therapeutics, Inc (NASDAQ: DWTX - Get Free Report) were up 1.7% during mid-day trading on Friday. The company traded as high as $3.17 and last traded at $3.06. Approximately 49,806 shares traded hands during trading, an increase of 47% from the average daily volume of 33,985 shares. The stock had previously closed
Dogwood Therapeutics, Inc. - Special Call
Dogwood Therapeutics, Inc. - Special Call Company Participants Greg Duncan - Chairman & CEO R. Gendreau - Chief Medical Officer Conference Call Participants Xun Lee - H.C.
